Buprenorphine Pharmacology Related to Addiction Treatment - 21
NCT00000239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2005-08-17
Summary
The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.
Conditions
- Opioid-Related Disorders
Interventions
- DRUG
-
Buprenorphine
Sponsors & Collaborators
-
University of Vermont
collaborator OTHER -
National Institute on Drug Abuse (NIDA)
lead NIH
Principal Investigators
-
Warren Bickel, Ph.D. · University of Vermont
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 0 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Alternate Day Buprenorphine Administration, Phase IX - 14
NCT00000232 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate-Day Buprenorphine Administration. Phase II - 4
NCT00000222 ·Status: COMPLETED ·Phase: PHASE1
-
Alternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221 ·Status: COMPLETED ·Phase: PHASE1
-
Alternate Day Buprenorphine Administration, Phase X - 15
NCT00000233 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate Day Buprenorphine Administration, Phase XI - 16
NCT00000234 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Maintenance for Opiate Dependence - 6
NCT00000357 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate-Day Buprenorphine Administration. Phase VI - 7
NCT00000225 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302 ·Status: COMPLETED ·Phase: PHASE3
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
NCT00000226 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Dosing Interval - 5
NCT00000209 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Opioid Taper on Opioid-Induced Hyperalgesia
NCT03063905 ·Status: TERMINATED
-
Alternate-Day Buprenorphine. Phase V - 6
NCT00000224 ·Status: COMPLETED ·Phase: PHASE1
-
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888 ·Status: COMPLETED ·Phase: NA
-
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355 ·Status: COMPLETED ·Phase: PHASE1
-
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate Day Buprenorphine Administration, Phase XII - 17
NCT00000235 ·Status: COMPLETED ·Phase: PHASE2
-
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
NCT00158236 ·Status: COMPLETED ·Phase: NA
-
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
NCT04192370 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance
NCT01642030 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458 ·Status: UNKNOWN
-
Sublingual Buprenorphine for Chronic Pain
NCT00612287 ·Status: UNKNOWN ·Phase: PHASE2
-
Buprenorphine's Dose Response Curve
NCT00460239 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
NCT01841931 ·Status: TERMINATED ·Phase: PHASE4